spacer
 
|

OVERVIEW
Intravitreal inhibitors of vascular endothelial growth factor A (VEGF-A) and corticosteroid delivery systems have revolutionized treatment for patients with diabetic macular edema (DME). Both classes of agents have broadly different mechanisms of action, which can present challenges in determining which type of agent to choose for a particular patient. Within each agent class, the different therapies have different pharmacokinetics, safety profiles, and in some cases, delivery methods. These sometimes overlapping/sometimes differing treatment options present challenges, including patient selection for various therapies, determining when to switch therapy, and the possible role of combination therapy. This program will offer real-time interactive learning to understand the pathophysiology of DME, as well as help clinicians differentiate the mechanism of action and safety/efficacy profiles of all available ophthalmic pharmacotherapy treatment options.

GOAL
The goal of this activity is to provide retina specialists with the most current knowledge of DME pathophysiology and treatment options for optimal management of patients with DME.

TARGET AUDIENCE
This activity is designed for retina specialists. No prerequisites required.

LEARNING OBJECTIVES
After completing this activity, the participant should be able to demonstrate the ability to:
  • DESCRIBE the pathophysiologic mechanisms that lead to DME.
  • DIFFERENTIATE the mechanism of action of currently available VEGF-A inhibitors for DME.
  • DIFFERENTIATE the safety/efficacy profiles of currently available corticosteroids for DME.

The estimated time to complete this activity: 60 minutes

Release date: August 10, 2015. Expiration date: August 10, 2016.

PARTICIPATING FACULTY
Quan Dong Nguyen, MD, MSc (Course Director)
Professor and Chair of Ophthalmology
McGaw Memorial Endowed Chair in Ophthalmology
Inaugural Director of the Stanley M. Truhlsen Eye Institute
University of Nebraska Medical Center
Omaha, Nebraska

David S. Boyer, MD
Clinical Professor of Ophthalmology
USC/Keck School of Medicine
Partner, Retina Vitreous Associates Medical Group
Los Angeles, California

Diana V. Do, MD
Professor of Ophthalmology
Vice Chair for Education
Director of the Carl Camras Center for Innovative Clinical Research
Director of the Ophthalmology Residency Training Program
Truhlsen Eye Institute
University of Nebraska Medical Center
Omaha, Nebraska

Michael Singer, MD
Managing Partner
Medical Center Ophthalmology Associates
Clinical Associate Professor
University of Texas Health Science Center
San Antonio, Texas

ACCREDITATION
The University of Nebraska Medical Center, Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Nebraska Medical Center, Center for Continuing Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

After reviewing this online activity, participants may receive a certificate by receiving a score of 70% or higher on the CME test and completing an evaluation. If participants score less than 70% on the CME test, they will be allowed to complete the examination 2 more times.

JOINT PROVIDERSHIP STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and ASiM.

DISCLAIMER
The University of Nebraska Medical Center, Center for Continuing Education, presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The University of Nebraska Medical Center, Center for Continuing Education assumes no liability for the information herein.

DISCLOSURE
It is the policy of the University of Nebraska Medical Center, Center for Continuing Education to ensure balance, independence, objectivity, and scientific rigor in all its sponsored educational activities. All faculty, activity planners, and staff involved in the development of this activity have disclosed any significant financial interest or other relationship with manufacturer(s) of any commercial product(s)/device(s) and/or provider(s) of commercial services included in this educational activity. A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The intent of this disclosure is not to prevent a faculty or staff member with a relevant financial or other relationship from participating in the activity, but rather to provide participants with information on which they can base their own judgments. The University of Nebraska Medical Center, Center for Continuing Education has identified and resolved any and all faculty conflicts of interest prior to the release of this activity.

FACULTY AND STAFF DISCLOSURES
Quan Dong Nguyen, MD, MSc: Board member/director for Bausch & Lomb, Incorporated; advisory board for Allergan, Inc, Regeneron Pharmaceuticals, Inc, and Santen Pharmaceutical Co, Ltd; consultant for AbbVie, Inc, and Genentech, Inc.

David S. Boyer, MD: Consultant and on a speakers’ bureau for Allergan, Inc, and Alcon; consultant and stock shareholder for Allegro Ophthalmics, LLC, Neurotech, Ohr Pharmaceutical, and Ophthotech Corporation; consultant and grants/research support recipient from Alcon, Genentech, Inc, Pfizer Inc, Regeneron Pharmaceuticals, Inc, and Santen, Inc; and a consultant for Aerpio Therapeutics, Bausch & Lomb Incorporated, Bayer, GlaxoSmithKline, Novartis Ophthalmics, ThromboGenics, and Santaris Pharma a/s.

Diana V. Do, MD: Consultant for Genentech, Inc, Regeneron Pharmaceuticals, Inc, and Santen Pharmaceutical Co, Ltd; advisory board for Allergan, Inc.

Michael Singer, MD: Consultant for Allergan, Inc, Genentech, Inc, and Regeneron Pharmaceuticals, Inc.

The planners or other members at the University of Nebraska Medical Center, Center for Continuing Education and ASiM, who control content have no relevant financial relationships to disclose.

PRIVACY POLICY
For the University of Nebraska Medical Center, Center for Continuing Education privacy policy, please click here.

FEE INFORMATION
There is no fee for this educational activity.

SYSTEM REQUIREMENTS
In order to ensure optimal viewing, please make sure your computer/device meets the following system requirements:
Processor (CPU): Intel Core i3 processor or greater; Windows 98/NT/200/XP or Mac OS 9/X or later, WebGL/HTML5 compatible browser such as Firefox, Chrome, or Safari; Windows Media Player 9.0 or later Flash player; 4 GB of RAM, DirectX9c video card with 512 MB RAM. Monitor settings: High color at 800 x 600 pixels, sound card and speakers, Adobe Acrobat Reader.

Please contact us with any technical questions or issues.

METHOD OF PARTICIPATION/HOW TO RECEIVE CREDIT
  • Review the activity objectives and CME/CE information.
  • Review the enduring material.
  • Successfully complete the post-test (75% accuracy).
  • Click on the link provided at the end of the activity and complete the online evaluation instrument, including the attestation of hours attended.
  • Print your certificate online.
  • The estimated time to complete this activity is 1.0 hour.

Table of Contents
Pre-Assessment

Innovative Therapies in Motion:
  An Update on Treatment Options for DME


Post-Assessment

procced to pretest


spacer  
  spacer
Advanced Studies in Medicine © 2014 Contact Us
spacer  
spacer